Known targets — ChEMBL curated mechanism
ACHESCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Gluconic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.87 |
| ▸ | PDE4A | P27815 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 2/20 | 0.31 |
| ▸ | TOP1 | P11387 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gluconic Acid SCHEMBL23566696 | 1.00 | LMNA (0.87) | LMNAPDE4AL3MBTL1USP2SLCO1B1 | |
| Gluconic Acid SCHEMBL4624626 | 1.00 | LMNA (0.87) | LMNAPDE4AL3MBTL1USP2SLCO1B1 | |
| Gluconic Acid SCHEMBL28953943 | 1.00 | LMNA (0.87) | LMNAPDE4AL3MBTL1USP2SLCO1B1 | |
| Gluconic Acid SCHEMBL28359238 | 1.00 | LMNA (0.87) | LMNAPDE4AL3MBTL1USP2SLCO1B1 | |
| Water SCHEMBL29706462 | 0.98 | LMNA (0.83) | LMNAPDE4AL3MBTL1USP2SLCO1B1 | |
| Gluconic Acid SCHEMBL24132 | 0.98 | LMNA (0.91) | LMNAPDE4AL3MBTL1USP2SLCO1B1 | |
| Gluconic Acid SCHEMBL20547381 | 0.98 | LMNA (0.91) | LMNAPDE4AL3MBTL1USP2SLCO1B1 | |
| Gluconic Acid SCHEMBL16180766 | 0.98 | LMNA (0.91) | LMNAPDE4AL3MBTL1USP2SLCO1B1 | |
| Gluconic Acid SCHEMBL23415272 | 0.98 | LMNA (0.91) | LMNAPDE4AL3MBTL1USP2SLCO1B1 | |
| Gluconic Acid SCHEMBL29661854 | 0.98 | LMNA (0.91) | LMNAPDE4AL3MBTL1USP2SLCO1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 397 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117244107-B | Surface porous super-hydrophilic implant without sand residue and preparation method thereof | 浙江科惠医疗器械股份有限公司 | 2026-05-19 | — | — | CN | claimed |
| WO-2025094212-A1 | STABLE AQUEOUS COMPOSITION OF CALCIUM GLUCONATE | EXTROVIS AG (CH) | 2025-05-08 | — | — | WO | claimed |
| EP-4537831-A2 | PHARMACEUTICAL COMPOSITIONS WITH ANTI-RANKL ANTIBODIES, CALCIUM AND VITAMIN D, SUITABLE FOR THE TREATMENT AND/OR PROPHYLAXIS OF DISORDERS OF THE BONE METABOLISM AND THERAPY-INDUCED SIDE EFFECTS SUCH AS HYPOCALCEMIA | Karl, Christoph (CH) | 2025-04-16 | — | — | EP | claimed |
| EP-4501330-A2 | PHARMACEUTICAL COMPOSITIONS WITH ANTI-RANKL ANTIBODIES, CALCIUM AND VITAMIN D, SUITABLE FOR THE TREATMENT AND/OR PROPHYLAXIS OF DISORDERS OF THE BONE METABOLISM AND THERAPY-INDUCED SIDE EFFECTS SUCH AS HYPOCALCEMIA | Karl, Christoph (CH) | 2025-02-05 | — | — | EP | claimed |
| CN-115707453-B | Calcium gluconate injection and preparation method thereof | 常州兰陵制药有限公司 | 2024-07-05 | — | — | CN | claimed |
| CN-117244107-A | Surface porous super-hydrophilic implant without sand residue and preparation method thereof | 浙江科惠医疗器械股份有限公司 | 2023-12-19 | — | — | CN | claimed |
| US-20230218754-A1 | PHARMACEUTICAL COMPOSITIONS WITH ANTI-RANKL ANTIBODIES, CALCIUM AND VITAMIN D | Karl, Christoph (CH) | 2023-07-13 | — | — | US | claimed |
| CN-116098860-A | Calcium gluconate injection and preparation method thereof | 绪必迪药业(沧州)有限公司 | 2023-05-12 | — | — | CN | claimed |
| CN-116099560-A | Ultra-high sulfur capacity two-dimensional carbon nano-sheet-based room-temperature oxidation desulfurization catalyst and preparation method and application thereof | 华东理工大学 | 2023-05-12 | — | — | CN | claimed |
| CN-115850057-A | Preparation method of calcium gluconate monohydrate | 常州兰陵制药有限公司 | 2023-03-28 | — | — | CN | claimed |
| US-9630437-B2 | Printable recording media | HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. (US) | 2017-04-25 | — | — | US | claimed |
| EP-3096958-A1 | PRINTABLE RECORDING MEDIA | Hewlett-Packard Development Company, L.P. (US) | 2016-11-30 | — | — | EP | claimed |
| US-20160339729-A1 | PRINTABLE RECORDING MEDIA | HEWLETT-PACKARD DEVELOPMENT COMPANY, LP (US) | 2016-11-24 | — | — | US | claimed |
| CN-105982914-A | Novel pharmaceutical composition of compound amino acid injection 18AA-I and application of pharmaceutical composition | 刘力 | 2016-10-05 | — | — | CN | claimed |
| CN-103610693-B | A kind of parenteral nutrition injection composition | LIAONING HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2015-12-30 | — | — | CN | claimed |
| US-20130095333-A1 | Surface Treated Medium | HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. | 2013-04-18 | — | — | US | claimed |
| WO-2008014610-A1 | DRUG DELIVERY COMPOSITIONS AND METHODS OF FORMING AND USING SAME | MIV THERAPEUTICS INC. (CA) | 2008-02-07 | — | — | WO | claimed |
| US-20050129644-A1 | Use of hydroxycarboxylic acids and salts thereof as complexing agents in reducing compositions for bleaching or permanently reshaping keratin fibres | L'OREAL S.A. (FR) | 2005-06-16 | — | — | US | claimed |
| US-20040234489-A1 | Use of a particular carboxylic acid or salts thereof as agents for conditioning keratin materials | L'OREAL S.A. (FR) | 2004-11-25 | — | — | US | claimed |
| WO-2001089533-A2 | PREPARATION FOR STABILIZING THE PROTECTIVE LAYER ON THE EPITHELIUM OF THE CORNEA OR THE ALVEOLI | SEED CAPITAL INVESTMENT-2 (SCI-2) B.V. (NL) | 2001-11-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040234489-A1 | Use of a particular carboxylic acid or salts thereof as agents for conditioning keratin materials | KRT18, SCO2, CA1 | LMNA 4114/4885PDE4A 4873/4885L3MBTL1 4528/4885 |
| US-20050129644-A1 | Use of hydroxycarboxylic acids and salts thereof as complexing agents in reducing compositions for bleaching or permanently reshaping keratin fibres | RARA, RARB, RARG | LMNA 186/4885PDE4A 2436/4885L3MBTL1 4860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.